ICU入住前早期使用平衡晶体液对脓毒症结局的影响
本研究为SMART试验的二次分析,纳入1641例内科ICU脓毒症患者,比较平衡晶体液(乳酸林格氏液或Plasma-Lyte A)与生理盐水(0.9%氯化钠)对30天院内死亡率的影响。在仅ICU控制液体选择的早期7个月,平衡晶体液组死亡率33.1% vs 生理盐水组32.9%(OR 1.14,95%CI 0.70-1.88);在急诊与ICU协同控制液体选择的后期15个月,平衡晶体液组死亡率24.9% vs 生理盐水组30.6%(OR 0.68,95%CI 0.52-0.89),交互作用P值为.07。结果提示平衡晶体液的获益主要体现在从急诊即开始控制液体选择的患者中。
要点
- 在急诊与ICU协同控制液体选择的时期,脓毒症患者使用平衡晶体液较生理盐水30天院内死亡率降低(24.9% vs 30.6%,OR 0.68,95%CI 0.52-0.89)。
- 仅在ICU阶段控制液体选择时,平衡晶体液与生理盐水组死亡率无显著差异(33.1% vs 32.9%,OR 1.14,95%CI 0.70-1.88)。
- 两个时期与随机分组的交互作用P值为.07,提示平衡晶体液的获益可能主要来自急诊即开始使用。
- 本研究为SMART试验的二次分析,纳入1641例内科ICU脓毒症患者,比较平衡晶体液与生理盐水。
适用人群与场景
- SMART试验中诊断为脓毒症的内科ICU患者,共1641例。
研究设计与关键结果
- 研究类型:SMART试验(集群交叉试验)的二次分析,比较平衡晶体液与生理盐水。
- 样本量:1641例脓毒症患者;仅ICU期367例,急诊与ICU期1274例。
- 仅ICU期:30天院内死亡率平衡晶体液组33.1%(47/142) vs 生理盐水组32.9%(74/225),OR 1.14(95%CI 0.70-1.88)。
- 急诊与ICU期:30天院内死亡率平衡晶体液组24.9%(170/682) vs 生理盐水组30.6%(181/592),OR 0.68(95%CI 0.52-0.89)。
- 交互作用P值为.07,提示平衡晶体液的获益主要出现在急诊与ICU协同控制液体选择的时期。
证据类型、等级与局限
- 证据类型:集群交叉试验的二次分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于脓毒症患者,作者认为从急诊即开始使用平衡晶体液(而非仅在ICU阶段)可能带来更大的生存获益。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Studies suggest that using balanced crystalloids (lactated Ringer's solution or Plasma-Lyte A) rather than saline (0.9% sodium chloride) may improve outcomes for patients with sepsis in the ED and ICU.
RESEARCH QUESTION: What is the relative impact on sepsis outcomes of fluid composition during early resuscitation in the ED vs after ICU admission?
STUDY DESIGN AND METHODS: We performed a secondary analysis of the Isotonic Solutions and Major Adverse Renal Events Trial (SMART) data set, examining medical ICU patients with a diagnosis of sepsis (n = 1,641). SMART was a cluster-crossover trial comparing balanced crystalloids vs saline among critically ill adults. During the first 7 months of SMART, fluid choice was controlled only in the ICU ("ICU-only period"). In the final 15 months, fluid choice was coordinated between the ED and ICU ("ED and ICU period"). We performed logistic regression modeling for 30-day in-hospital mortality with an interaction term between randomized group (balanced crystalloids vs saline) and study period (ICU-only period vs ED and ICU period).
RESULTS: Three hundred and sixty-seven patients with sepsis were enrolled during the ICU-only period and 1,274 were enrolled during the ED and ICU period. Thirty-day in-hospital mortality occurred in 47 of 142 patients (33.1%) in the balanced crystalloid group vs 74 of 225 patients (32.9%) in the saline group during the ICU-only period (OR, 1.14; 95% CI, 0.70-1.88) and in 170 of 682 patients (24.9%) in the balanced crystalloid group vs 181 of 592 patients (30.6%) in the saline group in the ED and ICU period (OR, 0.68; 95% CI, 0.52-0.89) (P value for interaction, .07), consistent with a beneficial effect of balanced crystalloid primarily in the ED and ICU period.
INTERPRETATION: Among patients with sepsis, the effect of balanced crystalloids vs saline on mortality was greater among patients for whom fluid choice was controlled starting in the ED compared with starting in the ICU.
参考来源
- Jackson KE, Wang L, Casey JD, et al. Effect of Early Balanced Crystalloids Before ICU Admission on Sepsis Outcomes. Chest. 2020. PMID: 32882244. doi:10.1016/j.chest.2020.08.2068
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。